The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
2021/09/17 by Mette Kruse Klausen, Morgane Thomsen, Gitta Wortwein +2 · 31 citations
Medicine · Neuroscience · #Diabetes Treatment and Management #Regulation of Appetite and Obesity #Neuropeptides and Animal Physiology
paper · pdf · doi:10.1111/bph.15677
Abstract
Drug, alcohol and tobacco use disorders are a global burden affecting millions of people. Despite decades of research, treatment options are sparse or missing, and relapse rates are high. Glucagon-like peptide 1 (GLP-1) is released in the small intestine, promotes blood glucose homeostasis, slows gastric emptying and reduces appetite. GLP-1 receptor agonists approved for treating Type 2 diabetes mellitus and obesity have received attention as a potential anti-addiction treatment. Studies in rodents and non-human primates have demonstrated a reduction in intake of alcohol and drugs of abuse, and clinical trials have been initiated to investigate whether the preclinical findings can be translated to patients. This review will give an overview of current findings and discuss the possible mechanisms of action. We suggest that effects of GLP-1 in alcohol and substance use disorders is mediated centrally, at least partly through dopamine signalling, but precise mechanisms are still to be uncovered. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc.
Cited by
- GLP-1 receptor agonists at the crossroads of obesity and addiction: A review of shared neurobiology and translational evidence
- Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder – A narrative review of available clinical evidence
- Connecting the dots: Understanding and addressing the metabolic impact of antipsychotic and antidepressant medications
- The gut and heart’s role in reward processing
- Effect of the <scp>GLP</scp> ‐1 receptor agonist exenatide on pro‐inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double‐blinded, placebo‐controlled clinical trial
- GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives
- Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling. [europepmc]
- Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study. [europepmc]
- The glucagon-like peptide-1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post-mortem brain study. [europepmc]
- Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. [europepmc]
- The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. [europepmc]
- Case Report: Semaglutide-associated depression: a report of two cases. [europepmc]
- Social, clinical, and policy implications of ultra-processed food addiction. [europepmc]
- Hypothalamic Supramammillary Control of Cognition and Motivation. [europepmc]
- GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. [europepmc]
- GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. [europepmc]
- Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. [europepmc]
- The emerging role of glucagon-like peptide 1 in binge eating. [europepmc]
- Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes. [europepmc]
- Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. [europepmc]
- Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys. [europepmc]
- IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. [europepmc]
- Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data. [europepmc]
- Risk of Suicidal Ideation or Attempts in Adolescents With Obesity Treated With GLP1 Receptor Agonists. [europepmc]
- The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. [europepmc]
- Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. [europepmc]
- Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. [europepmc]
- The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis. [europepmc]
- Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. [europepmc]
- Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. [europepmc]
- GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives. [europepmc]
Related